期刊文献+

盐酸乙哌立松联合塞来昔布治疗颈肩腰背痛75例疗效分析 被引量:1

Eperisone hydrochloride combined with celecoxib in the treatment of the neck pain and back pain:a analysis of 75 Cases
下载PDF
导出
摘要 目的评价盐酸乙哌立松联合应用塞来昔布对常见颈肩腰背痛的临床疗效。方法收集150例门诊颈肩腰背痛患者,随机分成单用药组(单独口服塞来昔布)和联合用药组(盐酸乙哌立松联合塞来昔布),采用VAS方法进行疗效评价,并观察2组的不良反应。结果联合用药组的总有效率为84%,显著高于单用药组的65.33%(P<0.05);联合用药组对急慢性颈肩软组织劳损、肩关节周围炎和急慢性腰肌劳损引起疼痛的疗效优于单用药组,但对腰椎间盘突出症引起疼痛的疗效与单用药组相当。2组发生不良反应的患者均为1例(1.33%)。结论盐酸乙哌立松联合塞来昔布治疗颈肩腰背痛可获得较好的镇痛疗效,优于单纯应用塞来昔布胶囊。 AIM To evaluate the clinical application of the eperisone hydrochloride combined with celecoxib in the treatment of the neck pain and back pain. METHODS One hundred and fifty cases with the above-mentioned disease were treated with either the celecoxib only or eperisone hydrochloride combined with celecoxib at random and were evaluated with the VAS method. The clinical results and the adverse drug reaction were recorded. RESULTS If the patients with the common symptoms like neck pain and back pain who had been excluded lumbar disc herniation were treated with eperisone hydrochloride and celecoxib, there were 84% effective rates, which was higher than those of the group taken celecoxib only. But the effect on the lumbar disc herniation of 2 groups was the same. There was one case with adverse drug reaction in both 2 groups ( 1.33 % ). CONCLUSION The clinical application of the eperisone hydrochloride combined with celecoxib would be better than celecoxib only in the treatment of the patients with neck pain and back pain to a mild extent.
出处 《中国临床药学杂志》 CAS 2007年第5期309-311,共3页 Chinese Journal of Clinical Pharmacy
关键词 乙哌立松 塞来昔布 疼痛 eperisone celecoxib pain
  • 相关文献

参考文献5

二级参考文献21

  • 1Siddall PJ. In: Cousins MJ. Bridenbaugh PO. eds. Neural Bolekade in Clinical Anesthesia and Management of Pain. 1998:675~713.
  • 2American Pain Society Quality Improvement Committee. JAMA,1995 ; 274 (23) : 1847~1880.
  • 3Joint Commission on Acchreditation of Healthcare Organizations.Jt Comm Perspect, 1999,19(5) : 6~8.
  • 4Silverstein FE, Faich G, Goldstein JL, et al. JAMA, 2000,284(10).1247~1255.
  • 5Mamdani M, Roehon PA, Junrlink DN, et al. BMJ, 2002,325(7365),624 ~ 627.
  • 6Leese PT, Hubbard RC, Karim A, et al. J Clin Pharmacol,2000,40(2):124~132.
  • 7Ekman EF, Fieehtner JJ, Levy S. et al. Am J Orthop,2002,31(8) :445~451.
  • 8Gimbel JS, Brugger A, Zhao W, et al. Clin Ther,2001,23(2):228~241.
  • 9Bellamy N,Buchanan WW,Goldsmith CH,et al. Validation study of Womac:a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee.J Rheumatol, 1988,
  • 10Warner TD,Giuliano F,Vojnovic I,et al. Non-steroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity:a full in vitro analysis. Proc Natl Acad Sci USA, 1996,12:7563-7568.

共引文献20

同被引文献5

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部